FIS
MPLT

FCPM III Services’s MapLight Therapeutics MPLT Stock Holding History

FCPM III Services’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.6M Hold
3,226,400
– – 9.08% 5
2025
Q4 		$56.7M Buy
+3,226,400
New +$54.1M 7.43% 5

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

FCPM III Services's MPLT Position: Q1 2026 in Review

FCPM III Services held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 3,226,400 shares worth $65.6M. The position accounts for 9.08% of the portfolio, ranked #5.

FCPM III Services first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • FCPM III Services held 3,226,400 shares of MapLight Therapeutics worth $65.6M as of Q1 2026.
  • FCPM III Services left its MapLight Therapeutics share count unchanged in Q1 2026.
  • MapLight Therapeutics made up 9.08% of FCPM III Services's portfolio in Q1 2026, its #5 holding.
  • FCPM III Services first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on FCPM III Services's 13F filing for Q1 2026, filed 15 May 2026.